Alnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) is scheduled to announce its earnings results before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of ($1.19) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Alnylam Pharmaceuticals Stock Down 0.4 %

Alnylam Pharmaceuticals stock opened at $169.34 on Tuesday. The company’s 50-day moving average price is $183.67 and its 200-day moving average price is $179.31. Alnylam Pharmaceuticals has a twelve month low of $148.10 and a twelve month high of $227.91. The company has a market cap of $21.25 billion, a PE ratio of -40.90 and a beta of 0.43.

Insider Buying and Selling

In related news, Director Michael W. Bonney sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total transaction of $5,850,000.00. Following the completion of the transaction, the director now owns 16,029 shares in the company, valued at approximately $3,125,655. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $240,703,000. Eaton Vance Management raised its holdings in shares of Alnylam Pharmaceuticals by 606.7% during the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock worth $50,005,000 after purchasing an additional 262,893 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 328.9% during the first quarter. Ameriprise Financial Inc. now owns 203,170 shares of the biopharmaceutical company’s stock worth $40,699,000 after purchasing an additional 155,795 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Alnylam Pharmaceuticals by 5,931.1% during the first quarter. Squarepoint Ops LLC now owns 133,228 shares of the biopharmaceutical company’s stock worth $26,688,000 after purchasing an additional 131,019 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after buying an additional 126,373 shares in the last quarter. Hedge funds and other institutional investors own 93.98% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ALNY shares. HC Wainwright restated a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, December 15th. Piper Sandler upped their price target on shares of Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an “overweight” rating in a report on Thursday, December 14th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, January 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday. Finally, Wells Fargo & Company started coverage on shares of Alnylam Pharmaceuticals in a report on Friday, December 8th. They set an “equal weight” rating and a $171.00 price target on the stock. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $230.95.

Get Our Latest Analysis on ALNY

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Read More

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.